National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Dictionary of Cancer Terms
In English   En español
Page Options
Print This Page
More NCI Dictionaries
NCI Drug Dictionary

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
In English   En español

ibritumomab tiuxetan (ih-brih-TOO-moh-mab ty-oo-EKS-eh-tan)

 A monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other types of B-cell tumors. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Ibritumomab binds to the protein called CD20, which is found on B cells. It is linked to the compound tiuxetan. This allows certain radioisotopes to be attached before it is given to a patient. It is a type of monoclonal antibody-chelator conjugate. Also called Zevalin.



Previous Definitions:hypoxic, hysterectomy, Hytrin, ibandronate, IBMFS
Next Definitions:IBS, ibuprofen, ICD, ICE, ICE regimen

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov